投资咨询业务资格:证监许可【2012】31号 == 宏观金融数据日报 ITG 国贸期货 世界500强投资企业 国贸期货有限公司 成为一流的衍生品综合服务商 B E W S B B B A 热 线 官 方 网 站 81 用版 400-8888-598 www.itf.com.cn ITCE 离期货 | | 国贸期货研究院 期货执业证号:F3074875; 2025/7/11 宏观金融研究中心 郑雨婷 投资咨询证号: Z0017779 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 品种 | 收盘价 | 较前值变动(bp) | 品种 | 收盘价 | 较前值变动 (bp) | | 4-6 | DR001 | 1.32 | 0.58 | DR007 | 1.49 | 1.78 | | E | GC001 | 1.16 | -27.50 | GC007 | 1.49 | -2.00 | | | SHBOR 3M | 1.56 | -0.30 | LPR 5年 | 3.50 | 0.00 | | D | 1年期国债 | 1.37 | 1.25 | 5 ...

投资咨询业务资格:证监证可【2012】31号 股 損 行 情 综 试 宏观金融数据日报 | | 国贸期货研究院 宏观金融研究中心 郑雨婷 | | 期货执业证号:F3074875; 投资咨询证号: Z0017779 | | 2025/7/4 | | | --- | --- | --- | --- | --- | --- | --- | | | 品种 | 收盘价 | 较前值变动(bp) | 品种 | 收盘价 | 较前值变动 (bp) | | | DR001 | 1.51 | -4.43 | DR007 | 1.91 | -3.79 | | | GC001 | 1.15 | -20.00 | GC007 | 1.49 | -1.50 | | ह | | | | | | | | | SHBOR 3M | 1.61 | -1.35 | LPR 5年 | 3.50 | 0.00 | | 而 | 1年期国债 | 1.34 | -0.50 | 5年期国债 | 1.49 | 0.50 | | 市 | | | | | | | | | 10年期国债 | 1.65 | 0.10 | 10年期美债 | 4.30 | 4.00 | | ...

宏观金融数据日报 | | 国贸期货研究院 期货执业证号:F3074875; 2025/7/3 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 宏观金融研究中心 郑雨婷 投资咨询证号: Z0017779 | | | | | | | | 较前值变动 品种 | 收盘价 | 较前值变动(bp) | 品种 | 收盘价 | | | | | | | | | (bp) | | स्टे | DR001 | 1.51 | 14.09 | DR007 | 1.91 | 20.92 | | E | GC001 | 1.35 | -11.00 | GC007 | 1.50 | -8.00 | | F | SHBOR 3M | 1.62 | -0.85 | LPR 5年 | 3.50 | 0.00 | | 场 | 1年期国债 | 1.34 | -0.50 | 5年期国债 | 1.49 | 0.50 | | 与 | 10年期国债 | 1.65 | 0.10 | 10年期美债 | 4.26 | 2.00 | | 流 | 回顾:央行昨日开展了3315亿元7天期逆回购操作 ...

交银国际研究 每日晨报 2025 年 7 月 3 日 今日焦点 | 北方华创 | | 002371 CH | | --- | --- | --- | | 国产半导体设备龙头：成长性与韧性兼备，首 | | 评级: 买入 | | 予买入 | | | | 收盘价: 人民币 443.30 | 目标价: 人民币 530.00 | 潜在涨幅: +19.6% | | 王大卫, PhD, CFA | Dawei.wang@bocomgroup.com | | 半导体行业国产替代最核心的环节：正如之前主题报告中所提到的，我 们看好国产半导体设备行业前景，并关注龙头公司北方华创。 下游需求持续旺盛，国产设备市占率提升：中国内地半导体设备市场在 全球市场的份额从 2015 年的 13%升至 2024 年的 42%。在这个过程中， 北方华创业绩在上行周期中表现出高成长性，在下行周期中韧性较强。 与市场一致预测同比下降不同，我们预测中国内地 2025 年市场将保持增 长，达 500 亿美元。进口设备占比呈下降趋势，我们估算从 2015 年的 91.8%到 2024 年的 67.6%。我们预测北方华创 2025 年在内地半导体设备 市场 ...

AI + mRNA 技术平台亮相研发日：公司近期举办研发日活动，集中展示其完全整合且本地化的AI + mRNA 平台，及基于该平台的多款mRNA 肿瘤药物研发进展：1）个性化肿瘤治疗性疫苗EVM16 目前 已在小鼠黑色素瘤模型中验证疗效并展现出与PD-1 抗体存在协同作用。其IIT 研究的初步结果显示，即 使低起始剂量，也能在晚期肿瘤患者中激发特异性T 细胞反应，具有良好的免疫原性。2）通用型现货 肿瘤治疗性疫苗EVM14 同时靶向5种肿瘤相关抗原，适用于多种鳞癌，临床前研究发现其具备诱导免疫 记忆、降低肿瘤复发的潜力，正同步推进中美双报。3）自体生成CAR-T 项目也已在动物模型中验证有 效，具备现货型、无需淋巴耗竭、剂量可控等优势，展现了开发用于肿瘤及自身免疫疾病的潜力。 可逆BTK 治疗膜性肾病更新优异数据：公司公布了共价可逆BTK 抑制剂EVER001 治疗膜性肾病的 Ib/IIa 期数据。试验招募抗PLA2R 自抗体阳性的患者，分为低剂量组（100mg QD x 4 周 + 100mg BID x 32 周）和高剂量组（200mg BID x 36 周），36 周治疗后接受16 周随访。结果显示：1 ...

mRNA 平台开发稳步推进，可逆 BTK 膜性肾病数据优异；上调目标价 | 买入 | | | | --- | --- | --- | | 1 | 年股价表现 | | | 250% | 1952 HK | 恒生指数 | | 200% | | | | 150% | | | | 100% | | | | 50% | | | | 0% -50% | | | 股份资料 交银国际研究 公司更新 | 医药 | 收盘价 | 目标价 | 潜在涨幅 | 2025 年 7 月 2 日 | | --- | --- | --- | --- | --- | | 62.20 | 港元 | 港元 72.50↑ | +16.6% | | | 云顶新耀 (1952 HK) | | | | | | 52周高位 (港元) | 65.15 | | --- | --- | | 52周低位 (港元) | 18.28 | | 市值 (百万港元) | 20,198.83 | | 日均成交量 (百万) | 13.36 | | 年初至今变化 (%) | 28.51 | | 200天平均价 (港元) | 47.94 | | 资料来源 : FactSet | | 丁 ...

Core Viewpoint - The latest phase data from the 1b/2a clinical trial of EVER001 shows promising efficacy and safety in treating primary membranous nephropathy (pMN), supporting its potential as a treatment for autoimmune glomerular diseases characterized by proteinuria [2][3][4]. Group 1: Clinical Trial Results - As of March 21, 2025, the ongoing 1b/2a clinical trial has collected long-term data, with 11 patients in the low-dose group followed for 52 weeks, and 16 and 12 patients in the high-dose group completing 24 and 36 weeks of treatment, respectively [1][3]. - The geometric mean levels of anti-PLA2R antibodies decreased by 62.2% and 87.3% in the low and high-dose groups at 12 weeks, with both groups showing over 93% reduction at 24 weeks [1][3]. - The 24-hour proteinuria geometric mean values decreased by 57.0% and 67.6% at 24 weeks for the low and high-dose groups, respectively, with further reductions to 76.7% and 80.6% at 36 weeks, maintained until the 52-week follow-up [4][5]. Group 2: Safety and Tolerability - EVER001 demonstrated good safety and tolerability, with most adverse events being mild to moderate and transient, consistent with previous observations [1][3][6]. - No clinically significant adverse events commonly associated with other BTK inhibitors, such as bleeding or severe infections, were observed [3][6]. Group 3: Market Potential and Future Development - The company aims to accelerate the global clinical development of EVER001, which has the potential to address the unmet medical needs of over 10 million patients with pMN and other autoimmune kidney diseases [5][15]. - Currently, there are no approved drugs for the treatment of pMN globally, highlighting the significant market opportunity for EVER001 [4][6]. - The company plans to initiate Phase 3 clinical trials and engage with regulatory authorities in the U.S. and China to expedite the development process [6][17]. Group 4: Mechanism and Advantages - EVER001 is a next-generation covalent reversible BTK inhibitor, offering advantages such as better selectivity and reduced off-target toxicity compared to traditional irreversible BTK inhibitors [5][13]. - The drug's mechanism allows for rapid and sustained immune and clinical responses, with significant reductions in antibody levels and proteinuria observed early in treatment [11][12][13]. Group 5: Broader Applications - The company believes that EVER001 may also be effective for other autoimmune diseases, including IgA nephropathy and lupus nephritis, due to its mechanism of action [15][18]. - There is a significant unmet need in these conditions, with millions of patients potentially benefiting from this treatment [15][18].

Core Viewpoint - The overnight repo rates at the exchange have increased, with GC001 reported at 3.45% and R001 at 3.31% at midday closing [1] Group 1 - The GC001 rate, which reflects the general collateral overnight repo rate, is currently at 3.45% [1] - The R001 rate, indicating the reverse repo rate, stands at 3.31% [1]

Core Viewpoint - The article highlights the rapid growth of China's innovative pharmaceutical companies, particularly in the context of supportive government policies and the increasing commercialization of their products, exemplified by the strategic shift of CloudTop New Horizon towards self-developed mRNA technology and its potential for global expansion [1][12]. Group 1: Policy Support and Market Dynamics - Recent government policies, including the State Council's approval of the "Full Chain Support for Innovative Drug Development Implementation Plan," have significantly boosted the innovative drug sector in China [1]. - In Q1 2025, the "License-out" transaction amount for Chinese innovative drugs reached $36.929 billion, indicating a surge in outbound transactions [1]. Group 2: CloudTop New Horizon's Strategic Shift - CloudTop New Horizon is transitioning from a "License-in" model to a self-developed innovative drug company, marking a significant strategic transformation [1][12]. - The company will hold its first mRNA technology platform R&D day on June 27, showcasing its self-research capabilities and signaling a potential value release [1]. Group 3: Commercialization and Revenue Projections - CloudTop New Horizon has successfully commercialized several key products, including Nefukang® and Yijia®, with projected sales reaching 10 billion yuan by 2030 [2][3]. - Nefukang® has seen a significant increase in sales following its inclusion in the medical insurance system, with expectations for revenue to double in the second half of the year [3][4]. Group 4: Product Pipeline and Market Potential - The company anticipates that Nefukang® could achieve peak sales of 5 billion yuan, while Yijia® is expected to reach similar sales figures due to its potential in the ulcerative colitis market [4][5][6]. - CloudTop New Horizon's product matrix, including Nefukang®, Yijia®, and the pipeline product Cefepime-Tazobactam, is projected to exceed 10 billion yuan in sales by 2030 [6]. Group 5: mRNA Platform Development - The mRNA platform is gaining attention from multinational pharmaceutical companies, with potential business development (BD) collaborations on the horizon [7][12]. - The company has developed a diverse pipeline within its mRNA platform, including personalized tumor therapeutic vaccines and CAR-T therapies, which are expected to attract further investment and partnerships [8][9]. Group 6: EVER001 Clinical Data and Global Expansion - EVER001, a new generation covalent reversible BTK inhibitor, has shown promising clinical data, with plans for global development and potential overseas licensing agreements [10][12]. - The positive clinical results for EVER001 in treating primary membranous nephropathy have garnered interest from multiple multinational pharmaceutical companies, indicating a strong market potential [11][12].

| 品种 | 收盘价 | 较前一日变动 (%) | 品种 | 收盘价 | 我前一日变 动(%) | | --- | --- | --- | --- | --- | --- | | 沪深300 | 3870 | -0.09 | IF当月 | 3869 | 0.0 | | 上证50 | 2684 | -0.04 | IH当月 | 2681 | 0.1 | | 中证500 | 5751 | -0.29 | IC当月 | 5748 | -0.1 | | 中证1000 | 6141 | -0.10 | IM当月 | 6130 | 0.0 | | IF成交量 | 95630 | -6.4 | IF持仓量 | 237778 | 0.5 | | IH成交量 | 50679 | 6.0 | IH持仓量 | 82576 | -0.5 | | IC成交量 | 86313 | -0.1 | IC持仓量 | 218236 | 0.2 | | IM成交量 | 179958 | 4.1 | IM持仓量 | 329756 | 1.7 | 投资咨询业务资格:证监许可【2012】31号 == 宏观金融数据日报 | | 国贸期货研究院 宏观金融研 ...